Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clarity, Curevac, Durect, Emalex, Finch, Freeline, Genfit, Hookipa, Immutep, Nuvalent, Pneumagen, Taiga, Terns, Yumanity.

Investors were thrilled when Roche Holding AG subsidiary Genentech Inc. and AC Immune SA reported top-line results from the Lauriet trial on Aug. 31, giving a positive jolt to AC Immune’s stock on the day of the announcement. At the Clinical Trials in Alzheimer’s Disease 2021 meeting, the reaction of the medical community was more skeptical.

Yumanity Therapeutics Inc. CEO Richard Peters said his firm is “in the driver’s seat” with regard to partnering options or going it alone, after YTX-7739 hit the primary endpoints in a phase Ib Parkinson’s disease (PD) study. Wall Street seemed less than certain about the success, knocking shares (NASDAQ: YMTX) down $2.83, or 33.4%, to close at $5.65.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Aldeyra, Alligator, Alx, Amylyx, Aravive, Ascletis, Beigene, Compass, Curasen, Eli Lilly, Exelixis, Helixmith, Horizon, Immatics, Immunocore, Incyte, Iterion, Moderna, Neuroplast, Noxopharm, Oncoimmune, Praxis, Scynexis, Sinovac, Suzhou Alphamab, Tonix, Ultimovacs, Vigeo, Xencor, Zymeworks.

Compass Pathways plc rolled out favorable top-line findings from the largest randomized, controlled, double-blind psilocybin therapy study ever completed, showing that COMP-360 at 25 mg yielded a highly statistically significant and clinically relevant reduction in symptom severity after three weeks in patients with treatment-resistant depression (TRD) .

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acurx, Affimed, Alnylam, Asklepios, Astrazeneca, Bayer, BMS, Bugworks, Crinetics, Curis, Diamedica, Diamond, Galmed, GSK, Ionctura, Kalvista, Neoimmune, Nkgen, Novartis, Oncoinvent, Pieris, Regeneron, Selecta, Servier, Teva, TFF, Urovant.

Results from two pivotal phase III trials testing Glaxosmithkline plc's daprodustat against anemia due to chronic kidney disease (CKD) found the oral hypoxia-inducible factor prolyl hydroxylase inhibitor helped both non-dialysis and dialysis patients improve or maintain hemoglobin levels without increased cardiovascular risk vs. standard-of-care erythropoietin stimulating agents. Though already approved in Japan as Duvroq, what future the drug might face in the U.S., where the same-class drug roxadustat garnered an FDA complete response letter, remained an open question.